NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® ...
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...
IO Biotech has resorted to halving its workforce after the FDA knocked back its plans to seek approval for its cancer vaccine. The therapeutic vaccine, called Cylembio, failed to beat Merck & Co.’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback